List of Excipients in Branded Drug TUKOL MAX ACTION DM MAX

Generic Drugs Containing TUKOL MAX ACTION DM MAX

Company	Ingredient	NDC	Excipient
Genomma Lab USA Inc	guaifenesin and dextromethorphan hbr	50066-004	CELLULOSE, MICROCRYSTALLINE
Genomma Lab USA Inc	guaifenesin and dextromethorphan hbr	50066-004	HYPROMELLOSE
Genomma Lab USA Inc	guaifenesin and dextromethorphan hbr	50066-004	MAGNESIUM STEARATE
Genomma Lab USA Inc	guaifenesin and dextromethorphan hbr	50066-004	POVIDONE K25

What are the Most Frequently-Used Excipients in TUKOL MAX ACTION DM MAX?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	HYPROMELLOSE
1	MAGNESIUM STEARATE
1	POVIDONE K25

TUKOL MAX ACTION DM MAX Excipient Strategy and Commercial Opportunities

Last updated: August 15, 2026

TUKOL MAX ACTION DM MAX is an over-the-counter oral cough product positioned around dual symptom relief: dextromethorphan hydrobromide for cough suppression and guaifenesin for chest congestion. Its commercial opportunity is driven less by drug-substance exclusivity and more by taste, dosing convenience, sugar content, preservative system, retail price, packaging, and brand distribution.

The product is likely exposed to rapid private-label and store-brand substitution because its active ingredients are established OTC monograph ingredients. Excipient optimization can create differentiation, but most improvements will be difficult to protect with broad pharmaceutical patents unless they produce a measurable stability, bioavailability, sensory, or manufacturing advantage.

What is TUKOL MAX ACTION DM MAX?

TUKOL MAX ACTION DM MAX is an oral liquid containing dextromethorphan hydrobromide and guaifenesin. The product is intended for cough suppression and expectoration of phlegm associated with the common cold or respiratory irritation.

Attribute	Product assessment
Brand	TUKOL
Product	MAX ACTION DM MAX
Dosage form	Oral liquid
Primary actives	Dextromethorphan hydrobromide and guaifenesin
Therapeutic category	OTC cough suppressant and expectorant
Regulatory pathway	FDA OTC monograph framework
Likely commercial format	Multi-dose bottle with dosing cup
Prescription patent estate	None expected
Biosimilar relevance	None
Paragraph IV relevance	None for the marketed OTC product
Main competitive risks	Private-label substitution, price competition, flavor rejection, retailer delisting

FDA’s OTC monograph for cough, cold, bronchodilator, and antiasthmatic drug products identifies permitted active ingredients, uses, warnings, and labeling requirements. Dextromethorphan is recognized as an antitussive, while guaifenesin is recognized as an expectorant.[1]

What excipients are used in TUKOL MAX ACTION DM MAX?

The product’s excipient system is expected to include a sweetener base, humectant, acidulant and buffer, preservative, flavor system, colorant, and purified water. Exact inactive ingredients should be confirmed against the current package label or FDA product record before a regulatory or freedom-to-operate decision.

A representative formulation architecture is as follows:

Excipient function	Likely materials or formulation options	Commercial purpose
Vehicle	Purified water	Dissolves or disperses active ingredients
Sweetener	High-fructose corn syrup, sucrose, sorbitol, or other polyols	Masks bitterness and supports viscosity
Humectant	Glycerin, sorbitol, propylene glycol	Improves mouthfeel and solubilization
Acidulant	Citric acid	Controls pH and improves flavor
Buffer	Sodium citrate	Stabilizes pH during shelf life
Preservative	Sodium benzoate or equivalent system	Controls microbial growth
Flavor	Fruit, berry, citrus, or medicinal flavor	Reduces dextromethorphan bitterness
Cooling agent	Menthol, where included	Creates a throat-cooling sensation
Colorant	Certified synthetic color or natural color	Supports product identity
Processing aid	Chelator, antifoam, or viscosity modifier	Improves stability and manufacturing performance

Dextromethorphan is intensely bitter, and guaifenesin can produce an unpleasant medicinal taste at the concentrations used in cough syrups. The highest-value excipient work therefore concerns taste masking, aroma management, and aftertaste reduction.

How does the excipient system affect product performance?

Taste masking and patient adherence

Taste is the principal formulation barrier. Dextromethorphan can create a bitter, lingering aftertaste. Guaifenesin contributes bulk solids and can increase the perception of medicinal flavor. A syrup platform can address these issues through several mechanisms:

1. Sweetness from sugars or polyols.
2. Viscosity from glycerin or polymeric thickening agents.
3. Acidification with citric acid.
4. Flavor layering using fruit, citrus, berry, or menthol notes.
5. Physical or chemical taste-masking systems.

Simple sweetness can create a problem if it produces excessive syrupiness or a delayed bitter rebound. A balanced formulation typically requires sensory testing at the end of the dosing window, not only at initial contact.

pH and chemical stability

The acidulant-buffer system affects preservative efficacy, flavor, color, and active stability. Sodium benzoate is more effective in acidic formulations because the undissociated form has greater antimicrobial activity. Excessive acidity can produce an unpleasant taste and may increase packaging compatibility concerns.

A commercial development program should establish a pH target that balances:

• preservative performance;
• dextromethorphan and guaifenesin stability;
• flavor acceptability;
• color stability;
• container compatibility; and
• microbial robustness after opening.

The formulation should be tested under accelerated and long-term conditions in the final bottle, closure, liner, dosing cup, and label configuration.

Sugar and calorie profile

A sugar-containing syrup can provide strong taste masking and familiar mouthfeel, but it limits use by consumers managing diabetes, dental health, or calorie intake. A sugar-free version using sorbitol, glycerin, sucralose, acesulfame potassium, or a combination could expand the addressable market.

Sugar-free development has technical costs. Polyols can produce cooling effects, gastrointestinal discomfort at higher exposures, and a thinner or more artificial mouthfeel. The product may require viscosity adjustment, flavor redesign, and revised warning or tolerance analysis.

Preservative strategy

Aqueous multi-dose products require microbial control throughout the labeled shelf life and, in practice, after repeated opening. Sodium benzoate is commercially familiar and compatible with acidic systems. Alternative strategies include potassium sorbate, parabens, phenoxyethanol, or preservative-reduced packaging.

A preservative-free or low-preservative version could support premium positioning, but it would require a stronger microbiological control strategy. Options include:

• unit-dose sachets;
• single-use cups;
• metered-dose liquid dispensers;
• improved closure systems;
• low-water-activity formulations; or
• validated aseptic manufacturing.

The packaging cost and consumer-use complexity may outweigh the premium unless the product targets pediatric, sensitive-consumer, or specialty retail channels.

What formulation patents could protect an improved TUKOL product?

The base combination of dextromethorphan and guaifenesin is unlikely to support strong composition-of-matter protection. The more realistic intellectual-property opportunities are formulation-specific.

Potential patentable concepts

Innovation	Potential claim focus	Commercial value
Taste-masked liquid	Specific sweetener, flavor, polymer, or complexing-agent ratios	High if sensory data show superiority
Sugar-free syrup	Polyol and high-intensity sweetener system with defined viscosity	Moderate to high
Extended stability	pH, buffer, preservative, and antioxidant combination	Moderate
Low-volume dose	Higher concentration with acceptable taste and stability	High if dosing convenience improves
Unit-dose package	Stable liquid in sachet, cup, or metered dispenser	Moderate
Reduced-color formula	Colorant-free or natural-color system with stability data	Moderate
Pediatric formulation	Age-specific flavor, dose delivery, and safety profile	Commercially meaningful but regulatory-sensitive
Spray or lozenge	Alternative delivery system for the same active combination	Potentially high
Manufacturing process	Mixing sequence, temperature control, deaeration, or preservative incorporation	Narrow but potentially defensible

A patent application would need more than a conventional list of excipients. Stronger claims would require comparative data showing unexpected stability, improved taste scores, lower microbial risk, reduced dosing volume, or improved physical properties.

What is the FDA regulatory status of TUKOL MAX ACTION DM MAX?

The product is an OTC drug, not a biologic and not a conventional prescription product listed in the Orange Book. Its regulatory position is tied primarily to the applicable OTC monograph, labeling requirements, current good manufacturing practice, and the manufacturer’s product-specific compliance obligations.

Orange Book status

The Orange Book generally identifies approved prescription and certain other drug products with therapeutic-equivalence information. An OTC cough syrup marketed under the monograph pathway does not ordinarily receive the same Orange Book patent-listing treatment as a new prescription drug application product.[2]

Paragraph IV challenges

Paragraph IV litigation is not the normal competitive mechanism for a monograph-compliant OTC cough syrup. A competing company can generally enter by developing a compliant product, obtaining the required establishment and product registrations, meeting labeling requirements, and satisfying FDA manufacturing standards.

Biosimilar risk

Biosimilar competition does not apply. TUKOL MAX ACTION DM MAX is a small-molecule oral liquid, not a biologic.

When does TUKOL MAX ACTION DM MAX lose exclusivity?

The product does not appear to depend on a conventional patent or regulatory exclusivity period. Its market protection is primarily brand-based and distribution-based.

Protection type	Expected relevance
New chemical entity exclusivity	Not applicable
Orphan-drug exclusivity	Not applicable
Biologic exclusivity	Not applicable
Orange Book patent listing	Not expected for the OTC monograph product
Paragraph IV entry barrier	Not applicable
Trademark protection	Potentially relevant
Trade dress	Potentially relevant
Formulation patent	Possible for a differentiated version
Retail distribution agreements	Commercially important
Consumer recognition	Main durable advantage

Generic or private-label entry can occur without waiting for a patent expiration date if the competing product complies with the OTC monograph and does not infringe valid formulation, packaging, trademark, or trade-dress rights.

How strong is the patent estate for TUKOL MAX ACTION DM MAX?

The likely patent estate is weak for the base product and potentially moderate for a redesigned formulation.

Base-product strength

The active ingredients are old, widely used, and available in competing cough products. A patent covering only the combination of dextromethorphan and guaifenesin would face significant validity and obviousness risk unless it claims a technically unusual ratio, dosage form, or clinical effect.

Formulation strength

A formulation patent can be stronger if it includes:

• tightly defined excipient ranges;
• a demonstrated taste-masking effect;
• a specific pH and preservative relationship;
• a stability improvement under challenging storage conditions;
• reduced dosing volume;
• improved preservative-free multidose performance; or
• a novel delivery device.

The claims should be supported by head-to-head data against standard syrup formulations. Without comparative evidence, conventional excipient combinations are vulnerable to obviousness challenges.

Trademark and trade dress

For this category, trademark and packaging rights may have more practical value than patents. TUKOL brand recognition, bottle design, color scheme, labeling, and retailer placement can delay substitution even when technically equivalent products are available.

What commercial opportunities exist for excipient innovation?

Sugar-free and diabetic-friendly products

A sugar-free TUKOL variant could target consumers who avoid high-sugar syrups. The strongest commercial proposition would combine:

• low-calorie sweetening;
• familiar syrup viscosity;
• reduced polyol gastrointestinal burden;
• no artificial aftertaste;
• clear front-panel communication; and
• packaging suitable for pharmacies and mass retail.

Lower-volume dosing

A more concentrated product could reduce the dose volume and improve portability. This opportunity is attractive for adult consumers, but concentration changes require careful evaluation of taste, dosing-device accuracy, labeling, and accidental-overdose risk.

Premium taste platform

A superior flavor system could support a premium SKU, especially if sensory testing shows lower bitterness and less medicinal aftertaste than leading products. Patentability would depend on the specific composition and comparative results.

Clean-label positioning

A product using natural flavors, natural colors, and a simplified excipient list could appeal to selected consumers. The market opportunity is real but constrained by the taste and stability demands of dextromethorphan-containing liquids.

Single-dose packaging

Unit-dose packaging can reduce contamination risk, improve travel use, and support institutional or convenience channels. The drawbacks are higher packaging cost, greater material consumption, and slower household dispensing.

Pediatric and family segmentation

A child-oriented product could use a lower-intensity flavor, age-appropriate dosing tools, and caregiver-focused labeling. The regulatory and safety analysis must address pediatric dosing, accidental ingestion, and the FDA’s restrictions and warnings for cough and cold products in young children.[3]

How does TUKOL compare with competing cough products?

Product strategy	TUKOL opportunity	Principal weakness
Standard DM/guaifenesin syrup	Broad familiar positioning	Easy private-label substitution
Mucinex DM-type extended-release tablet	Liquid dosing and rapid-use convenience	Less convenient for travel and storage
Dextromethorphan-only syrup	Clear cough-suppression message	No expectorant benefit
Guaifenesin-only syrup	Chest-congestion positioning	No cough-suppression benefit
Sugar-free liquid	Differentiated consumer segment	Taste and viscosity challenges
Premium natural-label syrup	Retail differentiation	Higher cost and stability burden
Unit-dose liquid	Portability and hygiene	Packaging expense

What manufacturing and IP barriers affect the product?

The main manufacturing barriers are process consistency and microbiological control rather than active-ingredient synthesis. Critical process parameters include:

• order of excipient addition;
• dissolution temperature;
• pH adjustment;
• deaeration;
• flavor incorporation;
• preservative dispersion;
• fill-volume control; and
• bottle and closure compatibility.

A manufacturer with validated syrup processes, strong sensory-development capabilities, and efficient contract-packaging access can compete without owning drug-substance IP.

Potential manufacturing know-how includes flavor premix preparation, low-foam processing, controlled addition of volatile flavor components, and methods for maintaining uniformity during filling. Trade-secret protection may be more practical than patent protection for these process details.

What litigation, licensing, and settlement risks apply?

No major Paragraph IV or biosimilar litigation pathway is expected for the OTC monograph product. The most relevant legal risks are:

• trademark infringement;
• trade-dress disputes;
• false or misleading comparative advertising;
• label and warning compliance;
• product-liability claims;
• manufacturing deviations; and
• supplier or contract-manufacturer disputes.

Licensing opportunities are more likely to involve flavor technology, taste-masking systems, dispensing devices, packaging, or retail distribution than active pharmaceutical ingredients. A licensee should seek rights covering the specific jurisdiction, dosage form, formulation range, manufacturing process, and packaging configuration.

What generic launch scenarios exist?

Immediate compliant private-label entry

A retailer or generic manufacturer can launch a similar OTC product using the same active ingredients and a compliant formulation. This is the highest-probability competitive scenario.

Premium reformulation launch

A competitor could introduce a sugar-free, lower-volume, better-tasting, or unit-dose product. This would compete on consumer experience rather than ingredient novelty.

Retailer-exclusive product

A retailer may use a store-brand version with lower pricing and comparable labeling. This scenario places pressure on TUKOL’s wholesale pricing and shelf placement.

Patent-protected reformulation

A redesigned TUKOL product could create a narrower barrier if supported by valid formulation or device patents. The barrier would apply to the claimed formulation, not necessarily to all dextromethorphan-guaifenesin products.

Key Takeaways

• TUKOL MAX ACTION DM MAX is an OTC dextromethorphan-guaifenesin oral liquid.
• Its principal commercial vulnerability is private-label substitution, not traditional prescription-generic entry.
• The most valuable excipient opportunities are taste masking, sugar reduction, viscosity control, preservative optimization, and lower-volume dosing.
• The base active combination is unlikely to support strong new-drug patent protection.
• Formulation patents require comparative stability, sensory, or manufacturing data.
• Orange Book, Paragraph IV, and biosimilar pathways are generally not central to this product.
• Trademark, trade dress, retail distribution, and consumer preference may provide greater practical protection than active-ingredient patents.
• A sugar-free, better-tasting, lower-volume, or unit-dose version offers the clearest product-development opportunities.

FAQs

Can a competitor copy the TUKOL MAX ACTION DM MAX excipient system?

A competitor can develop a substantially similar OTC formulation, but it must comply with applicable FDA requirements and avoid infringing valid patents, trademarks, trade dress, or proprietary formulation rights.

Can taste masking create a patentable TUKOL formulation?

Yes, but the claims should cover a specific composition or process supported by comparative evidence showing an unexpected sensory or stability benefit.

Is high-fructose corn syrup a strategic weakness for TUKOL?

It can limit appeal among consumers seeking sugar-free or lower-calorie products. A successful reformulation would need to preserve viscosity and taste while avoiding excessive polyol cooling or gastrointestinal effects.

Could a TUKOL liquid be converted into a tablet or lozenge?

Yes. A tablet, orally disintegrating tablet, chewable, lozenge, or film could improve portability, but each format creates new taste-masking, dose-uniformity, dissolution, and labeling requirements.

What is the best commercial excipient opportunity?

A sugar-free, lower-volume liquid with validated bitterness reduction and stable preservative performance offers the strongest combination of consumer differentiation, retail relevance, and potential formulation-IP value.

References

1. U.S. Food and Drug Administration. (2024). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. Electronic Code of Federal Regulations.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2023). Use caution when giving cough and cold products to kids. FDA Consumer Updates.